Back to top
more

Seattle Genetics, Inc. (SGEN)

(Delayed Data from NSDQ)

$67.25 USD

67.25
574,388

+0.33 (0.49%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Seattle Genetics (SGEN) to Receive Milestone Fee from Glaxo

by Zacks Equity Research

Seattle Genetics (SGEN) to win a milestone fee from GlaxoSmithKline following the EU approval of Blenrep, developed by the latter. Blenrep is made using the company's proprietary technology.

Seattle Genetics (SGEN) Q2 Earnings Beat, Adcetris Aids Sales

by Zacks Equity Research

Seattle Genetics (SGEN) reports a narrower-than-expected loss and beats sales estimates in the second quarter of 2020.

Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 6.90% and 8.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck's Keytruda Gets Priority Review for Lymphoma Indication

by Zacks Equity Research

FDA grants priority review to Merck's (MRK) regulatory application seeking label expansion of Keytruda as second-line treatment for relapsed or refractory classical Hodgkin lymphoma.

Seattle Genetics' Adcetris Progresses Well Amid Competition

by Zacks Equity Research

Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. Further, label expansions of the drug should continue to boost the top line.

Sweta Killa headshot

Nasdaq's Excels in Weekly Performance: 5 Best Stocks in ETF

by Sweta Killa

In a tug of war between bulls and bears, the Dow Jones and S&P 500 gained at least 1% each last week while the Nasdaq Composite Index advanced over 3%.

Why Is Seattle Genetics (SGEN) Up 14.6% Since Last Earnings Report?

by Zacks Equity Research

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Merck's (MRK) Keytruda Successful in Several Cancer Studies

by Zacks Equity Research

Merck (MRK) announces positive data from several cancer studies evaluating Keytruda across multiple indications.

Seattle Genetics' Adcetris Label Expands in EU for Lymphoma

by Zacks Equity Research

Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.

Sweta Killa headshot

Nasdaq ETF (QQQ) Joins $100 Billion Club: 10 Stock Winners

by Sweta Killa

Invesco QQQ (QQQ), which tracks the Nasdaq 100 Index, joined the $100 billion club of AUM last week.

Reata (RETA) Q1 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Reata (RETA) reports narrower-than-expected loss but misses revenue estimates for first-quarter 2020. Shares down.

Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q1 Loss

by Zacks Equity Research

Spectrum Pharma (SPPI) misses bottom-line estimates for the first quarter and records no revenues.

BioDelivery (BDSI) Beats on Q1 Earnings, Withdraws Guidance

by Zacks Equity Research

BioDelivery's (BDSI) strong Belubca sales drive the topline. Symproic further boosts revenues. Stock up.

Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q1 revenues increase year over year.

Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses

by Zacks Equity Research

Allogene (ALLO) reports no revenues for the first quarter of 2020.

Seattle Genetics (SGEN) Q1 Earnings Beat, Adcetris Aids Sales

by Zacks Equity Research

Seattle Genetics (SGEN) reports narrower-than-expected loss in Q1 while its revenues too beat estimates.

Amarin's (AMRN) Q1 Loss In Line With Estimates, Sales Beat

by Zacks Equity Research

Amarin's (AMRN) strong revenue growth in the first quarter is attributable to continued solid demand for its cardiovascular drug, Vascepa.

Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 20.99% and 10.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Perrigo (PRGO) reports decent first-quarter 2019 results. The addition of products following Ranir acquisition and stock piling due to COVID-19 boosts sales in the quarter.

Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat

by Zacks Equity Research

Alkermes (ALKS) beats earnings and sales estimates for the first quarter of 2020. The company withdraws its previously provided outlook for 2020 amid uncertainty related to coronavirus.

Here's Why Seattle Genetics (SGEN) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Seattle Genetics (SGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More

by Zacks Equity Research

Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.

What's in Store for Unum Therapeutics' (UMRX) Q1 Earnings?

by Zacks Equity Research

During Unum Therapeutics' (UMRX) upcoming Q1 earnings call, investor focus will be on the company's progress pertaining to its preclinical program, BOXR1030, for treating solid tumor cancers.